Retrospective analysis of FDA FAERS data identifies real-world safety concerns with tirzepatide beyond clinical trial reporting, including GI events and hypoglycemia patterns.
Key findingRetrospective analysis of FDA FAERS data identifies real-world safety concerns with tirzepatide beyo
What the researchers found
Retrospective analysis of FDA FAERS data identifies real-world safety concerns with tirzepatide beyond clinical trial reporting, including GI events and hypoglycemia patterns.
Why it matters
Relevant to expanding peptide-based therapeutic applications.
The numbers in context
FAERS reports from 2022 to Q1 2025 analyzed using proportional reporting ratio and related disproportionality methods.
How the study worked
Methodology detailed in publication.
Who was studied
Patients with reported adverse events from tirzepatide in the FDA FAERS database (2022-2025)
What this study cannot tell us
Limitations in publication.
How to read the evidence
Based on study design in publication.
When this study was published
Published in 2025.
The bigger picture
Contributes to the growing evidence for peptide therapeutics.
Questions still open
- Long-term implications?
- Comparison to existing evidence?
- Next research steps?
Common questions
What does this mean?
How reliable?
Read the original research
Real-World Safety Concerns of Tirzepatide: A Retrospective Analysis of FAERS Data (2022-2025).
Healthcare (Basel, Switzerland), 13(18)
Citation
Almansour, Hadi A; Thaibah, Hilal A; Alfarhan, Moaddey; Al-Qahtani, Saeed A; Khardali, Amani A; Alshammari, Thamir M. (2025). Real-World Safety Concerns of Tirzepatide: A Retrospective Analysis of FAERS Data (2022-2025).. Healthcare (Basel, Switzerland), 13(18). https://doi.org/10.3390/healthcare13182259